Jaffey Jared A, Amorim Juliana, DeClue Amy E
Am J Vet Res. 2018 Oct;79(10):1064-1070. doi: 10.2460/ajvr.79.10.1064.
OBJECTIVE To determine the in vitro effects of calcitriol on indicators of immune system function in blood samples collected from healthy dogs. SAMPLE Blood samples from 8 healthy adult dogs. PROCEDURES Blood samples were incubated with calcitriol (10M) or control substance for 24 hours. Afterward, lipopolysaccharide (LPS)-, lipoteichoic acid (LTA)-, and N-acetylmuramyl-l-alanyl-d-isoglutamine hydrate (MDP)-stimulated leukocyte production of tumor necrosis factor (TNF) and interleukin-10 (IL10) were measured with a canine-specific multiplex assay. Phagocytosis of opsonized Escherichia coli and leukocyte expression of constitutive toll-like receptor 4 (TLR4) were evaluated via flow cytometry. Blood samples from 3 dogs were used to create a concentration-response curve to evaluate whether the observed cytokine modulation was concentration dependent. RESULTS Incubation of canine blood samples with calcitriol resulted in significant decreases in LPS-, LTA-, and MDP-stimulated leukocyte production of TNF but not IL10. Blunting of TNF production was concentration dependent. Leukocyte calcitriol exposure had no significant effect on phagocytosis and TLR4 expression. CONCLUSIONS AND CLINICAL RELEVANCE These data indicated that calcitriol induced an anti-inflammatory shift in canine leukocytes exposed to LPS, LTA, and MDP in vitro, without altering phagocytosis or TLR4 expression. Thus, calcitriol could represent a novel candidate immunomodulatory treatment for dogs.
目的 确定骨化三醇对从健康犬采集的血液样本中免疫系统功能指标的体外影响。样本 8 只健康成年犬的血液样本。程序 将血液样本与骨化三醇(10μM)或对照物质孵育24小时。之后,用犬特异性多重检测法测量脂多糖(LPS)、脂磷壁酸(LTA)和N - 乙酰胞壁酰 - L - 丙氨酰 - D - 异谷氨酰胺水合物(MDP)刺激的白细胞产生肿瘤坏死因子(TNF)和白细胞介素 - 10(IL - 10)的情况。通过流式细胞术评估调理过的大肠杆菌的吞噬作用和组成型Toll样受体4(TLR4)的白细胞表达。使用3只犬的血液样本绘制浓度 - 反应曲线,以评估观察到的细胞因子调节是否呈浓度依赖性。结果 犬血液样本与骨化三醇孵育导致LPS、LTA和MDP刺激的白细胞产生TNF显著减少,但对IL - 10无影响。TNF产生的减弱呈浓度依赖性。白细胞暴露于骨化三醇对吞噬作用和TLR4表达无显著影响。结论和临床意义 这些数据表明,骨化三醇在体外诱导暴露于LPS、LTA和MDP的犬白细胞发生抗炎转变,而不改变吞噬作用或TLR4表达。因此,骨化三醇可能是犬的一种新型免疫调节治疗候选药物。